We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SXTC market cap is 599.47k. The company's latest EPS is USD -10.4945 and P/E is -0.10.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 7.01M | 5.16M | 4.78M | 2.6M | 1.97M |
| Operating Income | 1.77M | -1.32M | -2.13M | -5.14M | -5.61M |
| Net Income | 1.54M | -10.29M | -2.75M | -5.74M | -5.94M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 17.47M | 21.7M | 34.55M | 33.55M | 29.55M |
| Total Liabilities | 6.36M | 12.3M | 18.59M | 17.12M | 14.86M |
| Total Equity | 11.11M | 9.4M | 15.96M | 16.43M | 14.69M |
| Market Cap | 599.47k |
| Price to Earnings Ratio | -0.10 |
| Price to Sales Ratio | 0.3 |
| Price to Cash Ratio | 0.03 |
| Price to Book Ratio | 0.04 |
| Dividend Yield | - |
| Shares Outstanding | 565.53k |
| Average Volume (1 week) | 515.57k |
| Average Volume (1 Month) | 2.44M |
| 52 Week Change | -77.71% |
| 52 Week High | 9.375 |
| 52 Week Low | 0.9401 |
| Spread (Intraday) | 0.01 (0.93%) |
| Company Name | China SXT Pharmaceuticals Inc |
| Address |
sertus chambers road town, tortola VG1110 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
